LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

82.48 -0.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

82

Max

82.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+2.78% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.1B

13B

Ankstesnė atidarymo kaina

82.75

Ankstesnė uždarymo kaina

82.48

Naujienos nuotaikos

By Acuity

34%

66%

97 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-28 15:29; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

2025-11-28 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-11-28 19:59; UTC

Rinkos pokalbiai

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

2025-11-28 19:47; UTC

Rinkos pokalbiai

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

2025-11-28 18:16; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-28 18:16; UTC

Rinkos pokalbiai

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

2025-11-28 18:08; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-11-28 18:08; UTC

Rinkos pokalbiai

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

2025-11-28 17:48; UTC

Rinkos pokalbiai

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

2025-11-28 17:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-11-28 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

2025-11-28 15:51; UTC

Rinkos pokalbiai

Canada Household Spending Edges Lower -- Market Talk

2025-11-28 15:33; UTC

Rinkos pokalbiai

Crude Futures Gain as U.S. Market Reopens -- Market Talk

2025-11-28 15:21; UTC

Rinkos pokalbiai

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

2025-11-28 15:13; UTC

Rinkos pokalbiai

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

2025-11-28 15:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-28 15:11; UTC

Rinkos pokalbiai

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

2025-11-28 14:51; UTC

Rinkos pokalbiai

Canada GDP Report Masks Fragile State of Economy -- Market Talk

2025-11-28 14:41; UTC

Rinkos pokalbiai

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

2025-11-28 14:37; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

2025-11-28 14:33; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-28 14:33; UTC

Rinkos pokalbiai

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

2025-11-28 14:20; UTC

Rinkos pokalbiai

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

2025-11-28 14:10; UTC

Rinkos pokalbiai

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

2025-11-28 13:39; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-28 13:39; UTC

Rinkos pokalbiai

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

2025-11-28 13:36; UTC

Rinkos pokalbiai

Canada's Economy Expands More Than Expected -- Market Talk

2025-11-28 13:29; UTC

Rinkos pokalbiai

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

2025-11-28 13:27; UTC

Rinkos pokalbiai

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

2025-11-28 13:19; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

2.78% į viršų

12 mėnesių prognozė

Vidutinis 85 USD  2.78%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

16

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

97 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat